Homologous Recombination Deficiency (HRD) Signature-3 in Ovarian and Uterine Carcinosarcomas Correlates with Preclinical Sensitivity to Olaparib, a Poly (Adenosine Diphosphate [ADP]-Ribose) Polymerase (PARP) Inhibitor-MedSci.cn

Homologous Recombination Deficiency (HRD) Signature-3 in Ovarian and Uterine Carcinosarcomas Correlates with Preclinical Sensitivity to Olaparib, a Poly (Adenosine Diphosphate [ADP]-Ribose) Polymerase (PARP) Inhibitor

Tymon-Rosario, JR; Manara, P; Manavella, D; Bellone, S; Siegel, E; Hartwick, T; Mutlu, L; Altwerger, G; Menderes, G; Ratner, E; Huang, GS; Clark, M; Andikyan, V; Azodi, M; Schwartz, PE; Ludmil, AB; Alessandro, S

REPRODUCTIVE SCIENCES, 2022; 29 (SUPPL 1): 96

科室
- - 订阅+
  - 更多科室
工具
服务

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

Homologous Recombination Deficiency (HRD) Signature-3 in Ovarian and Uterine Carcinosarcomas Correlates with Preclinical Sensitivity to Olaparib, a Poly (Adenosine Diphosphate [ADP]-Ribose) Polymerase (PARP) Inhibitor

科室

工具

服务